株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

敗血症診断市場の世界市場:技術別 (微生物、PCR、マイクロアレイ、イムノアッセイ、バイオマーカー)・製品別 (試薬、アッセイ、機器、ソフトウェア)・手法別・テストの種類別 (ラボ、POC)・病原体別 (細菌、真菌)・エンドユーザー別・地域別の将来予測 (2025年まで)

Sepsis Diagnostics Market by Technology (Microbiology, PCR, Microarray, Immunoassay, Biomarkers), Product (Reagents, Assay, Instruments, Software), Method, Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End User and Region - Global Forecast to 2025

発行 MarketsandMarkets 商品コード 937813
出版日 ページ情報 英文 200 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.54円で換算しております。
敗血症診断市場の世界市場:技術別 (微生物、PCR、マイクロアレイ、イムノアッセイ、バイオマーカー)・製品別 (試薬、アッセイ、機器、ソフトウェア)・手法別・テストの種類別 (ラボ、POC)・病原体別 (細菌、真菌)・エンドユーザー別・地域別の将来予測 (2025年まで) Sepsis Diagnostics Market by Technology (Microbiology, PCR, Microarray, Immunoassay, Biomarkers), Product (Reagents, Assay, Instruments, Software), Method, Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End User and Region - Global Forecast to 2025
出版日: 2020年05月15日 ページ情報: 英文 200 Pages
概要

世界の敗血症診断の市場規模は、2019年には4億2900万米ドル、2025年には7億米ドルと、8.5%のCAGRで成長する、と予想されています。

当レポートでは、世界の敗血症診断の市場について分析し、市場の基本構造や最新情勢、主な市場促進・阻害要因、市場動向の見通し (今後6年間分)、技術別・製品別・手法別・検査の種類別・病原体別・エンドユーザー別・地域別の詳細動向、市場競争の状態、主要企業のプロファイルなどを調査しております。

937813_4.2 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY_FIGURE 14

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概略

  • イントロダクション
  • 市場のダイナミクス
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
    • 課題

第6章 敗血症診断の市場:技術別

  • イントロダクション
  • 血液培養
  • イムノアッセイ (免疫学的検定)
  • 分子診断
    • PCR (ポリメラーゼ連鎖反応)
    • マイクロアレイ
    • ペプチド核酸蛍光in situハイブリダイゼーション (PNA FISH)
    • 症候群パネルベース検査
  • フローサイトメトリー
  • マイクロ流体
  • バイオマーカー

第7章 敗血症診断の市場:製品別

  • イントロダクション
  • 血液培地
  • アッセイ・試薬
  • 診断装置
  • ソフトウェア

第8章 敗血症診断の市場:手法別

  • イントロダクション
  • 従来型診断
  • 自動診断

第9章 敗血症診断の市場:病原体別

  • イントロダクション
  • 細菌性敗血症
    • グラム陰性菌敗血症
    • グラム陽性菌敗血症
  • 真菌性敗血症
  • その他の病原体

第10章 敗血症診断の市場:検査の種類別

  • イントロダクション
  • ラボ検査
  • PoC (ポイントオブケア) 検査

第11章 敗血症診断の市場:エンドユーザー別

  • イントロダクション
  • 病院
  • 病理検査室・参考検査室
  • 研究室・教育機関

第12章 敗血症診断の市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他の欧州諸国
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他のアジア太平洋諸国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他のラテンアメリカ諸国
  • 中東・アフリカ

第13章 競争環境

  • 概要
  • 市場シェア分析
  • 競争シナリオ
    • 製品の上市・承認
    • 事業提携・協力
    • 企業合併・買収 (M&A)
    • 市場拡張
  • 企業戦略の方向性:マッピング
    • 先駆的企業
    • 革新的企業
    • 活動的企業
    • 新規企業

第14章 企業プロファイル

  • BIOMERIEUX
  • BECTON, DICKINSON AND COMPANY
  • DANAHER
  • T2 BIOSYSTEMS
  • LUMINEX
  • ROCHE DIAGNOSTICS
  • THERMO FISHER SCIENTIFIC
  • BRUKER CORPORATION
  • ABBOTT
  • IMMUNEXPRESS
  • RESPONSE BIOMEDICAL
  • AXIS-SHIELD DIAGNOSTICS
  • CYTOSORBENTS
  • MITSUBISHI CHEMICAL EUROPE
  • EKF DIAGNOSTICS
  • 新規参入企業
    • SEEGENE
    • GENMARK DIAGNOSTICS
    • BODITECH MED
    • ALPHA LABORATORIES
    • ALIFAX S.R.L.

第15章 付録

図表

LIST OF TABLES

  • TABLE 1 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 47
  • TABLE 2 BLOOD CULTURE MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 2017-2025 (USD MILLION) 48
  • TABLE 3 BLOOD CULTURE MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 2017-2025 (USD MILLION) 48
  • TABLE 4 BLOOD CULTURE MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 2017-2025 (USD MILLION) 48
  • TABLE 5 BLOOD CULTURE MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 2017-2025 (USD MILLION) 49
  • TABLE 6 BLOOD CULTURE MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 2017-2025 (USD MILLION) 49
  • TABLE 7 BLOOD CULTURE MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 2017-2025 (USD MILLION) 49
  • TABLE 8 IMMUNOASSAYS MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 2017-2025 (USD MILLION) 51
  • TABLE 9 IMMUNOASSAYS MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 2017-2025 (USD MILLION) 51
  • TABLE 10 IMMUNOASSAYS MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 2017-2025 (USD MILLION) 51
  • TABLE 11 IMMUNOASSAYS MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 2017-2025 (USD MILLION) 52
  • TABLE 12 IMMUNOASSAYS MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 2017-2025 (USD MILLION) 52
  • TABLE 13 IMMUNOASSAYS MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 2017-2025 (USD MILLION) 52
  • TABLE 14 MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 53
  • TABLE 15 MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 2017-2025 (USD MILLION) 53
  • TABLE 16 MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 2017-2025 (USD MILLION) 54
  • TABLE 17 MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 2017-2025 (USD MILLION) 54
  • TABLE 18 MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 2017-2025 (USD MILLION) 54
  • TABLE 19 MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 2017-2025 (USD MILLION) 55
  • TABLE 20 MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 2017-2025 (USD MILLION) 55
  • TABLE 21 PCR MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 2017-2025 (USD MILLION) 56
  • TABLE 22 PCR MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 2017-2025 (USD MILLION) 56
  • TABLE 23 PCR MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 2017-2025 (USD MILLION) 56
  • TABLE 24 PCR MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 2017-2025 (USD MILLION) 56
  • TABLE 25 PCR MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 2017-2025 (USD MILLION) 57
  • TABLE 26 PCR MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 2017-2025 (USD MILLION) 57
  • TABLE 27 MICROARRAYS MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 2017-2025 (USD MILLION) 58
  • TABLE 28 MICROARRAYS MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 2017-2025 (USD MILLION) 58
  • TABLE 29 MICROARRAYS MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 2017-2025 (USD MILLION) 58
  • TABLE 30 MICROARRAYS MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 2017-2025 (USD MILLION) 59
  • TABLE 31 MICROARRAYS MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 2017-2025 (USD MILLION) 59
  • TABLE 32 MICROARRAYS MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 2017-2025 (USD MILLION) 59
  • TABLE 33 PNA-FISH MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 2017-2025 (USD MILLION) 60
  • TABLE 34 PNA-FISH MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 2017-2025 (USD MILLION) 60
  • TABLE 35 PNA-FISH MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 2017-2025 (USD MILLION) 60
  • TABLE 36 PNA-FISH MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 2017-2025 (USD MILLION) 61
  • TABLE 37 PNA-FISH MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 2017-2025 (USD MILLION) 61
  • TABLE 38 PNA-FISH MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 2017-2025 (USD MILLION) 61
  • TABLE 39 SYNDROMIC PANEL-BASED TESTING MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 2017-2025 (USD MILLION) 62
  • TABLE 40 SYNDROMIC PANEL-BASED TESTING MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 2017-2025 (USD MILLION) 62
  • TABLE 41 SYNDROMIC PANEL-BASED TESTING MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 2017-2025 (USD MILLION) 62
  • TABLE 42 SYNDROMIC PANEL-BASED TESTING MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 2017-2025 (USD MILLION) 63
  • TABLE 43 SYNDROMIC PANEL-BASED TESTING MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 2017-2025 (USD MILLION) 63
  • TABLE 44 SYNDROMIC PANEL-BASED TESTING MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 2017-2025 (USD MILLION) 63
  • TABLE 45 FLOW CYTOMETRY MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 2017-2025 (USD MILLION) 64
  • TABLE 46 FLOW CYTOMETRY MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 2017-2025 (USD MILLION) 64
  • TABLE 47 FLOW CYTOMETRY MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 2017-2025 (USD MILLION) 65
  • TABLE 48 FLOW CYTOMETRY MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 2017-2025 (USD MILLION) 65
  • TABLE 49 FLOW CYTOMETRY MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 2017-2025 (USD MILLION) 65
  • TABLE 50 FLOW CYTOMETRY MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 2017-2025 (USD MILLION) 65
  • TABLE 51 MICROFLUIDICS MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 2017-2025 (USD MILLION) 66
  • TABLE 52 MICROFLUIDICS MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 2017-2025 (USD MILLION) 67
  • TABLE 53 MICROFLUIDICS MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 2017-2025 (USD MILLION) 67
  • TABLE 54 MICROFLUIDICS MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 2017-2025 (USD MILLION) 67
  • TABLE 55 MICROFLUIDICS MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 2017-2025 (USD MILLION) 68
  • TABLE 56 MICROFLUIDICS MARKET FOR SEPSIS DIAGNOSIS, BY END USER, 2017 - 2025 (USD MILLION) 68
  • TABLE 57 BIOMARKERS MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 2017-2025 (USD MILLION) 69
  • TABLE 58 BIOMARKERS MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 2017-2025 (USD MILLION) 69
  • TABLE 59 BIOMARKERS MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 2017-2025 (USD MILLION) 69
  • TABLE 60 BIOMARKERS MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 2017-2025 (USD MILLION) 70
  • TABLE 61 BIOMARKERS MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 2017-2025 (USD MILLION) 70
  • TABLE 62 BIOMARKERS MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 2017-2025 (USD MILLION) 70
  • TABLE 63 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2017-2025 (USD MILLION) 72
  • TABLE 64 SEPSIS DIAGNOSTIC BLOOD CULTURE MEDIA MARKET, BY REGION, 2017-2025 (USD MILLION) 72
  • TABLE 65 SEPSIS DIAGNOSTIC ASSAYS & REAGENTS MARKET, BY REGION, 2017-2025 (USD MILLION) 73
  • TABLE 66 SEPSIS DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2017-2025 (USD MILLION) 74
  • TABLE 67 SEPSIS DIAGNOSTIC SOFTWARE MARKET, BY REGION, 2017-2025 (USD MILLION) 75
  • TABLE 68 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2017-2025 (USD MILLION) 77
  • TABLE 69 CONVENTIONAL DIAGNOSTICS MARKET, BY REGION, 2017-2025 (USD MILLION) 78
  • TABLE 70 AUTOMATED DIAGNOSTICS MARKET, BY REGION, 2017-2025 (USD MILLION) 79
  • TABLE 71 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 2017-2025 (USD MILLION) 81
  • TABLE 72 BACTERIAL SEPSIS MARKET, BY TYPE, 2017-2025 (USD MILLION) 81
  • TABLE 73 BACTERIAL SEPSIS MARKET, BY REGION, 2019-2025 (USD MILLION) 82
  • TABLE 74 CAUSES OF ADULT SEPSIS: GRAM-NEGATIVE BACTERIA 82
  • TABLE 75 GRAM-NEGATIVE BACTERIAL SEPSIS MARKET, BY REGION, 2019-2025 (USD MILLION) 83
  • TABLE 76 CAUSES OF ADULT SEPSIS: GRAM-POSITIVE BACTERIA 83
  • TABLE 77 GRAM-POSITIVE BACTERIAL SEPSIS MARKET, BY REGION, 2019-2025 (USD MILLION) 84
  • TABLE 78 FUNGAL SEPSIS MARKET, BY REGION, 2019-2025 (USD MILLION) 84
  • TABLE 79 OTHER PATHOGENS MARKET, BY REGION, 2017-2025 (USD MILLION) 85
  • TABLE 80 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2017-2025 (USD MILLION) 87
  • TABLE 81 LABORATORY SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 2017-2025 (USD MILLION) 88
  • TABLE 82 POINT-OF-CARE SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 2017-2025 (USD MILLION) 89
  • TABLE 83 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2017-2025 (USD MILLION) 91
  • TABLE 84 SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2017-2025 (USD MILLION) 92
  • TABLE 85 SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY REGION, 2017-2025 (USD MILLION) 92
  • TABLE 86 SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2017-2025 (USD MILLION) 93
  • TABLE 87 SEPSIS DIAGNOSTICS MARKET, BY REGION, 2017-2025 (USD MILLION) 95
  • TABLE 88 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2017-2025 (USD MILLION) 96
  • TABLE 89 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 97
  • TABLE 90 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 97
  • TABLE 91 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2017-2025 (USD MILLION) 97
  • TABLE 92 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 2017-2025 (USD MILLION) 98
  • TABLE 93 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2017-2025 (USD MILLION) 98
  • TABLE 94 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2017-2025 (USD MILLION) 98
  • TABLE 95 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2017-2025 (USD MILLION) 98
  • TABLE 96 US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 100
  • TABLE 97 US: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 101
  • TABLE 98 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 102
  • TABLE 99 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 102
  • TABLE 100 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2017-2025 (USD MILLION) 103
  • TABLE 101 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 103
  • TABLE 102 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 104
  • TABLE 103 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2017-2025 (USD MILLION) 104
  • TABLE 104 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 2017-2025 (USD MILLION) 104
  • TABLE 105 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2017-2025 (USD MILLION) 105
  • TABLE 106 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2017-2025 (USD MILLION) 105
  • TABLE 107 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2017-2025 (USD MILLION) 105
  • TABLE 108 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 107
  • TABLE 109 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 107
  • TABLE 110 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 108
  • TABLE 111 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 108
  • TABLE 112 UK: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 110
  • TABLE 113 UK: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 110
  • TABLE 114 ITALY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 111
  • TABLE 115 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 111
  • TABLE 116 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 112
  • TABLE 117 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 112
  • TABLE 118 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 113
  • TABLE 119 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 113
  • TABLE 120 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2017-2025 (USD MILLION) 115
  • TABLE 121 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 115
  • TABLE 122 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 115
  • TABLE 123 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2017-2025 (USD MILLION) 116
  • TABLE 124 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 2017-2025 (USD MILLION) 116
  • TABLE 125 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2017-2025 (USD MILLION) 116
  • TABLE 126 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2017-2025 (USD MILLION) 117
  • TABLE 127 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2017-2025 (USD MILLION) 117
  • TABLE 128 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 118
  • TABLE 129 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 118
  • TABLE 130 CHINA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 119
  • TABLE 131 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 120
  • TABLE 132 INDIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 121
  • TABLE 133 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 121
  • TABLE 134 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 122
  • TABLE 135 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 123
  • TABLE 136 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 123
  • TABLE 137 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 124
  • TABLE 138 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 125
  • TABLE 139 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 125
  • TABLE 140 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2017-2025 (USD MILLION) 126
  • TABLE 141 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 126
  • TABLE 142 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 127
  • TABLE 143 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2017-2025 (USD MILLION) 127
  • TABLE 144 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 2017-2025 (USD MILLION) 127
  • TABLE 145 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2017-2025 (USD MILLION) 128
  • TABLE 146 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2017-2025 (USD MILLION) 128
  • TABLE 147 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2017-2025 (USD MILLION) 128
  • TABLE 148 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 129
  • TABLE 149 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 129
  • TABLE 150 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 130
  • TABLE 151 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 130
  • TABLE 152 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 131
  • TABLE 153 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 131
  • TABLE 154 MIDDLE EAST AND AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION) 132
  • TABLE 155 MIDDLE EAST AND AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 2017-2025 (USD MILLION) 133
  • TABLE 156 MIDDLE EAST AND AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2017-2025 (USD MILLION) 133
  • TABLE 157 MIDDLE EAST AND AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 2017-2025 (USD MILLION) 133
  • TABLE 158 MIDDLE EAST AND AFRICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2017-2025 (USD MILLION) 134
  • TABLE 159 MIDDLE EAST AND AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2017-2025 (USD MILLION) 134
  • TABLE 160 MIDDLE EAST AND AFRICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2017-2025 (USD MILLION) 134

LIST OF FIGURES

  • FIGURE 1 RESEARCH DESIGN 22
  • FIGURE 2 BREAKDOWN OF PRIMARIES: GLOBAL SEPSIS DIAGNOSTICS MARKET 25
  • FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 26
  • FIGURE 4 MARKET SIZE ESTIMATION: SEPSIS DIAGNOSTICS MARKET 28
  • FIGURE 5 DATA TRIANGULATION METHODOLOGY 29
  • FIGURE 6 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2019 VS 2025 31
  • FIGURE 7 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019 VS 2025 32
  • FIGURE 8 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2019 VS 2025 32
  • FIGURE 9 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019 VS 2025 33
  • FIGURE 10 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 2019 VS 2025 34
  • FIGURE 11 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2018 34
  • FIGURE 12 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019 (USD MILLION) 35
  • FIGURE 13 RISING PREVALENCE OF SEPSIS IS DRIVING DEMAND FOR DIAGNOSTICS 36
  • FIGURE 14 BLOOD CULTURE SEGMENT WILL DOMINATE THE MARKET DURING 2019-2025 37
  • FIGURE 15 BLOOD CULTURE MEDIA SEGMENT TO DOMINATE THE GLOBAL SEPSIS DIAGNOSTICS PRODUCTS MARKET IN 2019 38
  • FIGURE 16 HOSPITALS SEGMENT TO DOMINATE THE ASIA PACIFIC MARKET DURING THE FORECAST PERIOD 38
  • FIGURE 17 GRAM-NEGATIVE BACTERIAL SEPSIS HOLDS LARGEST SHARE OF THE GLOBAL MARKET, BY PATHOGEN 39
  • FIGURE 18 ASIA PACIFIC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 39
  • FIGURE 19 SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 40
  • FIGURE 20 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT 96
  • FIGURE 21 APAC: SEPSIS DIAGNOSTICS MARKET SNAPSHOT 114
  • FIGURE 22 KEY DEVELOPMENTS BY LEADING MARKET PLAYERS IN THE SEPSIS DIAGNOSTICS MARKET, 2016-2019 135
  • FIGURE 23 SEPSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYERS, 2018 136
  • FIGURE 24 SEPSIS DIAGNOSTICS MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2019 140
  • FIGURE 25 BIOMERIEUX: COMPANY SNAPSHOT 141
  • FIGURE 26 BD: COMPANY SNAPSHOT 144
  • FIGURE 27 DANAHER: COMPANY SNAPSHOT 146
  • FIGURE 28 T2 BIOSYSTEMS: COMPANY SNAPSHOT (2019) 150
  • FIGURE 29 LUMINEX: COMPANY SNAPSHOT 152
  • FIGURE 30 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT 154
  • FIGURE 31 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 157
  • FIGURE 32 BRUKER: COMPANY SNAPSHOT 160
  • FIGURE 33 ABBOTT: COMPANY SNAPSHOT 163
  • FIGURE 34 CYTOSORBENTS: COMPANY SNAPSHOT 168
  • FIGURE 35 MITSUBISHI CHEMICAL EUROPE: COMPANY SNAPSHOT 171
  • FIGURE 36 EKF DIAGNOSTICS: COMPANY SNAPSHOT 172
目次
Product Code: MD 4575

"The global sepsis diagnostics market is projected to grow at a CAGR of 8.5% during the forecast period."

The global sepsis diagnostics market size is expected to reach USD 700 million by 2025 from USD 429 million in 2019, at a CAGR of 8.5%. The demand is expected to grow due to the rising incidence of sepsis, a growing number of surgical procedures, high incidence of hospital-acquired infections, and increasing availability of a wide variety of sepsis diagnostic devices. The sepsis diagnostics industry is segmented on the technology, product, method, pathogen, test type, end user, and region.

"The blood culture segment accounted for the largest share of the sepsis diagnostics industry, by end-user, in 2019."

Based on end-users, the sepsis diagnostics market is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. In 2019, blood culture accounted for the largest share of the market due to the increasing incidences of sepsis coupled with the growing adoption of blood culture techniques for the diagnosis of sepsis.

"The blood culture media segment accounted for the largest share of the sepsis diagnostics market, by product, in 2019."

The market, by product, is segmented into blood culture media, assays & reagents, instruments, and software. In 2019, the blood culture media segment accounted for the largest share of the sepsis diagnostics industry due to the usage of blood culture testing as the standard diagnostic method for the diagnosis and identification of sepsis across the globe.

"North America accounted for the largest share of the sepsis diagnostics market in 2019."

North America accounted for the largest share of the global market in 2019, followed by Europe. This can primarily be attributed to the extensive availability of advanced sepsis diagnostic technologies, well-established distribution channels, and significant public awareness about the clinical benefits of diagnostic products in risk assessment for infectious diseases.

Breakdown of supply-side primary interviews:

  • By Company Type: Tier 1 (48%), Tier 2 (36%), and Tier 3 (16%)
  • By Designation: C-level (10%), Director-level (14%), and Others (76%)
  • By Region: North America (40%), Europe (32%), APAC (20%), and RoW (8%)

Some of the prominent players in the sepsis diagnostics market are bioMerieux (France), Becton Dickinson Company (US), Danaher (US), Abbott Laboratories (US), Roche Diagnostics (Switzerland), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), and CytoSorbents (US).

Research Coverage:

This report studies the sepsis diagnostics market based on technology, product, method, pathogen, test type, end-user, and region. It studies significant factors (such as drivers and restraints) affecting the market growth. The report also analyzes opportunities and challenges in the market for stakeholders. It provides details of the competitive landscape for market leaders with respect to their growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.

Key Benefits of Buying the Report:

This report focuses on various levels of analysis-industry trends, market shares of top players, and company profiles, which together form basic views. It also analyzes the competitive landscape users emerging segments of the sepsis diagnostics market; and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

TABLE OF CONTENTS

1 INTRODUCTION 19

  • 1.1 OBJECTIVES OF THE STUDY 19
  • 1.2 MARKET DEFINITION 19
  • 1.3 MARKET SCOPE 20
    • 1.3.1 MARKETS COVERED 20
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY 20
  • 1.4 CURRENCY USED FOR THE STUDY 21
  • 1.5 STAKEHOLDERS 21

2 RESEARCH METHODOLOGY 22

  • 2.1 RESEARCH DATA 22
    • 2.1.1 SECONDARY DATA 23
      • 2.1.1.1 Secondary sources 24
    • 2.1.2 PRIMARY DATA 25
  • 2.2 MARKET ESTIMATION METHODOLOGY 26
    • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 27
    • 2.2.2 PROCEDURE-BASED MARKET ESTIMATION 27
    • 2.2.3 PRIMARY RESEARCH VALIDATION 28
  • 2.3 DATA TRIANGULATION 29
  • 2.4 RESEARCH ASSUMPTIONS 30
  • 2.5 RESEARCH LIMITATIONS 30

3 EXECUTIVE SUMMARY 31

4 PREMIUM INSIGHTS 36

  • 4.1 SEPSIS DIAGNOSTICS: MARKET OVERVIEW 36
  • 4.2 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY 37
  • 4.3 GEOGRAPHIC ANALYSIS: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT AND REGION 38
  • 4.4 APAC: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY AND END USER 38
  • 4.5 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN 39
  • 4.6 GEOGRAPHIC SNAPSHOT OF THE SEPSIS DIAGNOSTICS MARKET 39

5 MARKET OVERVIEW 40

  • 5.1 INTRODUCTION 40
  • 5.2 MARKET DINAMICS 40
    • 5.2.1 DRIVERS 41
      • 5.2.1.1 High incidence of sepsis 41
      • 5.2.1.2 Rising incidence of hospital-acquired infections 42
      • 5.2.1.3 Growing funding for sepsis-related research 42
    • 5.2.2 RESTRAINTS 43
      • 5.2.2.1 Unfavorable reimbursement scenario 43
      • 5.2.2.2 High cost of automated diagnostic devices 43
    • 5.2.3 OPPORTUNITIES 43
      • 5.2.3.1 Development of rapid diagnostic/POC techniques for early sepsis diagnosis 43
      • 5.2.3.2 Evolution of novel biomarkers for sepsis diagnosis 44
    • 5.2.4 CHALLENGES 44
      • 5.2.4.1 Lack of standard protocols and awareness 44
      • 5.2.4.2 Shortage of skilled healthcare professionals 45

6 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY 46

  • 6.1 INTRODUCTION 47
  • 6.2 BLOOD CULTURE 47
    • 6.2.1 BLOOD CULTURE HOLDS THE LARGEST SHARE OF THE TECHNOLOGY MARKET 47
  • 6.3 IMMUNOASSAYS 50
    • 6.3.1 PRODUCT DEVELOPMENT EFFORTS BY MAJOR PLAYERS HAVE ENSURED DEMAND FOR IMMUNOASSAYS 50
  • 6.4 MOLECULAR DIAGNOSTICS 53
    • 6.4.1 POLYMERASE CHAIN REACTION 55
      • 6.4.1.1 PCR holds the largest share of the molecular diagnostics market 55
    • 6.4.2 MICROARRAYS 57
      • 6.4.2.1 Simultaneous analysis capabilities, accuracy, and rapidity have driven the use of microarrays 57
    • 6.4.3 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION 60
      • 6.4.3.1 PNA-FISH kits allow for the rapid diagnosis of BSIs 60
    • 6.4.4 SYNDROMIC PANEL-BASED TESTING 61
      • 6.4.4.1 High costs and accuracy issues have affected test adoption 61
  • 6.5 FLOW CYTOMETRY 64
    • 6.5.1 LACK OF STANDARDIZED PROTOCOLS IS A KEY RESTRAINT IN THIS MARKET SEGMENT 64
  • 6.6 MICROFLUIDICS 66
    • 6.6.1 GROWING ADOPTION OF ADVANCED & RAPID TESTING WILL FAVOR MARKET GROWTH IN THIS SEGMENT 66
  • 6.7 BIOMARKERS 68
    • 6.7.1 DESPITE POTENTIAL, NO SINGLE IDEAL BIOMARKER HAS BEEN IDENTIFIED FOR SEPSIS DIAGNOSTICS 68

7 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT 71

  • 7.1 INTRODUCTION 72
  • 7.2 BLOOD CULTURE MEDIA 72
    • 7.2.1 BLOOD CULTURE MEDIA DOMINATE THE PRODUCTS MARKET 72
  • 7.3 ASSAYS & REAGENTS 73
    • 7.3.1 INCREASING AWARENESS HAS DRIVEN THE USE OF ASSAYS & REAGENTS 73
  • 7.4 INSTRUMENTS 74
    • 7.4.1 MARKET IS CHARACTERIZED BY A SHIFT FROM TRADITIONAL & MANUAL INSTRUMENTS TO AUTOMATED SYSTEMS 74
  • 7.5 SOFTWARE 75
    • 7.5.1 RISING USE OF AUTOMATED INSTRUMENTS WILL ENSURE DEMAND FOR SOFTWARE 75

8 SEPSIS DIAGNOSTICS MARKET, BY METHOD 76

  • 8.1 INTRODUCTION 77
  • 8.2 CONVENTIONAL DIAGNOSTICS 77
    • 8.2.1 CONVENTIONAL DIAGNOSTICS HOLDS LARGEST MARKET SHARE 77
  • 8.3 AUTOMATED DIAGNOSTICS 78
    • 8.3.1 AUTOMATED DIAGNOSTICS SEGMENT TO GROW AT THE HIGHEST CAGR 78

9 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN 80

  • 9.1 INTRODUCTION 81
  • 9.2 BACTERIAL SEPSIS 81
    • 9.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS 82
      • 9.2.1.1 Gram-negative bacteria cause ~50% of sepsis infections 82
    • 9.2.2 GRAM-POSITIVE BACTERIAL SEPSIS 83
      • 9.2.2.1 Cases of sepsis caused by gram-positive bacteria have risen in recent years 83
  • 9.3 FUNGAL SEPSIS 84
    • 9.3.1 FUNGEMIA IS THE SECOND-BIGGEST CAUSE OF BLOODSTREAM INFECTIONS 84
  • 9.4 OTHER PATHOGENS 85

10 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE 86

  • 10.1 INTRODUCTION 87
  • 10.2 LABORATORY TESTS 87
    • 10.2.1 LABORATORY TESTS ARE THE MOST COMMON AND PREFERRED MODE OF TESTING 87
  • 10.3 POINT-OF-CARE TESTS 88
    • 10.3.1 RAPIDITY AND CONVENIENCE HAVE DRIVEN DEMAND FOR POC TESTS 88

11 SEPSIS DIAGNOSTICS MARKET, BY END USER 90

  • 11.1 INTRODUCTION 91
  • 11.2 HOSPITALS 91
    • 11.2.1 HOSPITALS HOLD THE LARGEST SHARE OF THE SEPSIS DIAGNOSTICS MARKET 91
  • 11.3 PATHOLOGY & REFERENCE LABORATORIES 92
    • 11.3.1 INDEPENDENT LABORATORIES OFFER AFFORDABILITY AS WELL AS THE BENEFITS OF BUNDLED SERVICES 92
  • 11.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES 93
    • 11.4.1 GOVERNMENT SUPPORT AND RISING AWARENESS HAVE ENSURED DEMAND FOR MARKET PRODUCTS IN THIS SEGMENT 93

12 SEPSIS DIAGNOSTICS MARKET, BY REGION 94

  • 12.1 INTRODUCTION 95
  • 12.2 NORTH AMERICA 95
    • 12.2.1 US 99
      • 12.2.1.1 US is the largest market for sepsis diagnostics 99
    • 12.2.2 CANADA 101
      • 12.2.2.1 Growing availability of sepsis diagnostic products to support market growth in Canada 101
  • 12.3 EUROPE 103
    • 12.3.1 GERMANY 106
      • 12.3.1.1 Germany accounted for the largest share of the European market 106
    • 12.3.2 FRANCE 107
      • 12.3.2.1 High incidence and rising awareness have supported the demand for sepsis diagnostics in France 107
    • 12.3.3 UK 109
      • 12.3.3.1 Government support and rising awareness are key drivers in the UK 109
    • 12.3.4 ITALY 110
      • 12.3.4.1 Sluggish growth in the Italian healthcare sector in the last few years to restrain the market growth 110
    • 12.3.5 SPAIN 111
      • 12.3.5.1 Rising sepsis incidence to drive market growth in Spain 111
    • 12.3.6 REST OF EUROPE 112
  • 12.4 ASIA PACIFIC 113
    • 12.4.1 JAPAN 117
      • 12.4.1.1 Significant growth in pneumonia and infectious disease incidence to support market growth in Japan 117
    • 12.4.2 CHINA 118
      • 12.4.2.1 Healthcare infrastructure improvements to support market growth in China 118
    • 12.4.3 INDIA 120
      • 12.4.3.1 Increasing patient population and rising number of surgical procedures are key growth drivers in India 120
    • 12.4.4 AUSTRALIA 122
      • 12.4.4.1 Increasing number of sepsis treatment procedures indicates growth potential in the Australian market 122
    • 12.4.5 SOUTH KOREA 123
      • 12.4.5.1 Rising healthcare spending supports market growth in South Korea 123
    • 12.4.6 REST OF ASIA PACIFIC 124
  • 12.5 LATIN AMERICA 125
    • 12.5.1 BRAZIL 129
      • 12.5.1.1 Brazil accounted for the largest share of the LATAM market 129
    • 12.5.2 MEXICO 130
      • 12.5.2.1 Rising medical tourism to support market growth in Mexico 130
    • 12.5.3 REST OF LATIN AMERICA 131
  • 12.6 MIDDLE EAST & AFRICA 132
    • 12.6.1 HIGH CONSUMPTION OF IMMUNE SYSTEM-SUPPRESSING MEDICATIONS IS DRIVING SEPSIS OCCURRENCE 132

13 COMPETITIVE LANDSCAPE 135

  • 13.1 OVERVIEW 135
  • 13.2 MARKET SHARE ANALYSIS 136
  • 13.3 COMPETITIVE SCENARIO 137
    • 13.3.1 PRODUCT LAUNCHES AND APPROVALS, 2016-2020 137
    • 13.3.2 PARTNERSHIPS AND COLLABORATIONS, 2016-2020 137
    • 13.3.3 MERGERS AND ACQUISITIONS, 2016-2020 138
    • 13.3.4 MARKET EXPANSION, 2016-2020 138
  • 13.4 COMPETITIVE LEADERSHIP MAPPING 138
    • 13.4.1 VISIONARY LEADERS 139
    • 13.4.2 INNOVATORS 139
    • 13.4.3 DYNAMIC DIFFERENTIATORS 139
    • 13.4.4 EMERGING COMPANIES 139

14 COMPANY PROFILES 141

(Business Overview, Products Offered, Recent Developments, MnM View)*

  • 14.1 BIOMERIEUX 141
  • 14.2 BECTON, DICKINSON AND COMPANY 144
  • 14.3 DANAHER 146
  • 14.4 T2 BIOSYSTEMS 150
  • 14.5 LUMINEX 152
  • 14.6 ROCHE DIAGNOSTICS 154
  • 14.7 THERMO FISHER SCIENTIFIC 157
  • 14.8 BRUKER CORPORATION 160
  • 14.9 ABBOTT 163
  • 14.10 IMMUNEXPRESS 165
  • 14.11 RESPONSE BIOMEDICAL 166
  • 14.12 AXIS-SHIELD DIAGNOSTICS 167
  • 14.13 CYTOSORBENTS 168
  • 14.14 MITSUBISHI CHEMICAL EUROPE 171
  • 14.15 EKF DIAGNOSTICS 172
  • 14.16 EMERGING PLAYERS 174
    • 14.16.1 SEEGENE 174
    • 14.16.2 GENMARK DIAGNOSTICS 174
    • 14.16.3 BODITECH MED 175
    • 14.16.4 ALPHA LABORATORIES 176
    • 14.16.5 ALIFAX S.R.L. 177

Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

15 APPENDIX 178

  • 15.1 DISCUSSION GUIDE 178
  • 15.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 195
  • 15.3 AVAILABLE CUSTOMIZATIONS 197
  • 15.4 RELATED REPORTS 198
  • 15.5 AUTHOR DETAILS 199